Receipt date: 02/26/2009

Sheet

IDS Form PTO/SB/08: Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

F

Complete if Known				
Application Number	10/758,773			
Filing Date	January 16, 2004			
First Named Inventor	Seng H. CHENG			
Art Unit 1632				
Examiner Name	Shin-Lin Chen			
Attorney Docket Number	07680.0018-00000			

	U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS						
Examine	r	Cite	Document Number	Issue or	Name of Patentee or	Pages, Columns, Lines, Where	
Initials		No.	Number-Kind Code (# known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
/SC	/	1 US-5,179,023 01-12-1993		01-12-1993	CALHOUN et al.		
	Т	2	US-5,658,567	08-19-1997	CALHOUN et al.		
	T	3	US-5,834,266	11-10-1998	CRABTREE et al.		
		4	US-6,461,609	10-08-2002	CALHOUN et al.		
V	/	5	US-6,492,332	12-10-2002	DEMOPULOS et al.		
/SC	7	6	US-7,011,831	03-14-2006	CALHOUN et al.		

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

2

		NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
/SC/	7	BUECHNER et al., "Central Nervous System Involvement in Anderson-Fabry Disease: A Clinical and MRI Retrospective Study," <i>J. Neurol. Neurosurg. Psychiatry</i> 79(11):1249-1254 (2008) (published online Jun. 5, 2008).						
	8	FELLGIEBEL et al., "CNS Manifestations of Fabry's Disease," Lancet Neurol. 5:791-795 (2006).						
	g	MEHTA et al. Eds., Fabry disease Perspectives from 5 years of FOS, Table of Contents pp. vii-x (Oxford PharmaGenesis™ Ltd., 2006).						
	10	MOORE et al., "The Cerebral Vasculopathy of Fabry Disease," J. Neurol. Sci. 257:258-263 (2007).						
	11	Office Action issued in parent U.S. Application No. 09/884,526, mailed May 29, 2003 (Attorney Docket No. 07680.0019-00000).						
	12	Office Action issued in parent U.S. Application No. 09/884,526, mailed February 18, 2004 (Attorney Docket No. 07680.0019-00000).						
	13	Office Action issued in parent U.S. Application No. 09/884,526, mailed August 25, 2004 (Attorney Docket No. 07680.0019-00000).						
	14	Office Action issued in parent U.S. Application No. 09/884,526, mailed January 31, 2005 (Attorney Docket No. 07680.0019-00000).						
	15	Office Action issued in parent U.S. Application No. 09/884,526, mailed August 10, 2005 (Attorney Docket No. 07680.0019-00000).						
	16	Office Action issued in parent U.S. Application No. 09/884,526, mailed March 6, 2006 (Attorney Docket No. 07680.0019-00000).						
	17	Office Action issued in parent U.S. Application No. 09/884,526, mailed October 17, 2006 (Attorney Docket No. 07680.0019-00000).						
	18	Office Action issued in U.S. Application No. 11/762,689, mailed September 25, 2008 (Attorney Docket No. 07680.0019-01000).						
	19	PALADIN LABS INC., "Conditional Approval of Replagat™ (agalsidase alfa): Fact Sheet* Paladin Labs Inc., February 6, 2004 (Health Canada). Available online at http://www.hc-sc.gc.ca/dhp-mps/prodpharma/notices-avis/conditions/replagal_fs_fd_068304-eng.php.						
1/	20	TSUJI et al., "Signal Sequence and DNA-Mediated Expression of Human Lysosomal α-Galactosidase A," Eur. J. Biochem. 165:275-280 (1987).						
/SC/	21	U.S. Food and Drug Administration, Department of Health and Human Services Approval Letter to Genzyme Corporation regarding U.S. License No. 1596, dated April 24, 2003 (available online at http://www.ida.gov/oder/foi/appletter/2003/agalgen042403.htm).						

Receipt date: 02/26/2009 10758773 - GAU: 1632

02/20/2000				10/30/70 and.		
IDS Form PTO/SB/08: Substitute for form 1449A/PTO			Complete if Known			
			Application Number	10/758,773		
OPMATION F	ISCLOSU	IRF	Filing Date	January 16, 2004		
			First Named Inventor	Seng H. CHENG		
(Use as many sheets as necessary)			Art Unit	1632		
			Examiner Name	Shin-Lin Chen		
2	of	2	Attorney Docket Number	07680.0018-00000		
	/SB/08: Substitute for for FORMATION D ATEMENT BY	VSB/08: Substitute for form 1449A/PTO FORMATION DISCLOSU ATEMENT BY APPLICA (Use as many sheets as necessary)	SBIOS: Substitute for form 1449APTO FORMATION DISCLOSURE ATEMENT BY APPLICANT (Use as many sheets as necessary)	SBI08: Substitute for form 1449APTO FORMATION DISCLOSURE ATEMENT BY APPLICANT (Use as many sheets as necessary) CEADMIC Application Number Filing Date Filing Date Art Unit Examiner Name		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
/SC/	22	ZARATE et al., "Lysosomal Storage Disease 3: Fabry's disease," Lancet 372:1427-1435 (2008).	

Examiner Signature	/Shin Lin Chen/			Date Considered	05/12/2009
		 - 41	 		000 D. E. H.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

05/12/2009